International Patent: ANTIBODIES AGAINST LILRB1 AND/OR LILRB2, METHOD FOR PREPARING THE SAME, AND USE THEREOF

GENEVA, July 6 -- WUXI BIOLOGICS (SHANGHAI) CO., LTD. filed a patent application (CN2025/145846) for “ANTIBODIES AGAINST LILRB1 AND/OR LILRB2, METHOD FOR PREPARING THE SAME, AND USE THEREOF”. With publication no. WO/2026/139008, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: C07K 16/28

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....